The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal
meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital
discharge results in superior survival compared to standard initiation of ART started as an
outpatient.
Phase:
Phase 4
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Makerere University Mbarara University of Science and Technology National Institute of Allergy and Infectious Diseases (NIAID) University of Cape Town